• About us
• Contact

Advertisement

Organisation › Details

Boehringer Ingelheim China

Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim Germany, the company operates presently with a total of some 50,000 employees. Boehringer Ingelheim entered into the Chinese market in 1994, headquartered in Shanghai with more than 3500 employees. The major business focuses of BI China include human pharma, animal health and biopharmaceuticals. In recent years, BI has achieved continuous growth, outperformed the market average. BI has been certified as “China Top Employer” during 2014 to 2018. To become the premier multinational pharmaceutical company is the vision of Boehringer Ingelheim China. The company aims to bring more and better innovative products earlier to patients to enhance their health and life quality. *

 

	Start	1994-01-01 established
	Group	Boehringer Ingelheim (Group)
	Industry	pharmaceutical
	Region	Shanghai
	Country	China
	City	n. a. Shanghai
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Boehringer Ingelheim. (7/4/18). "Press Release: Boehringer Ingelheim Extends “One-Stop-Shop” Service with New Fill & Finish Capabilities in China". Shanghai.
		Record changed: 2023-07-10

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (4/9/24). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets". Ingelheim & Shanghai....
• [2] Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan....
• [3] Burning Rock Biotech Ltd.. (10/31/23). "Press Release: Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics"....
• [4] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim Partners with Precision Health Research, Singapore to Bring Future Medical Breakthroughs to Patients". Ingelheim & Singapore....
• [5] Boehringer Ingelheim. (12/20/22). "Press Release: Boehringer Ingelheim Announces Appointments to Board of Managing Directors". Ingelheim....
• [6] Hong Kong Science and Technology Parks (HKSTP). (6/17/22). "Press Release: HKSTP and Boehringer Ingelheim Venture Fund Launch Co-Incubation Programme to Fast-track R&D in Infectious Diseases and Immunology". Hong Kong....
• [7] Brainomix Ltd.. (12/16/21). "Press Release: Brainomix Closes £16M ($21.2M) Financing Round to Expand Its Proven AI-enabled Platform Beyond Stroke". Oxford....
• [8] Aragen Life Sciences Pvt. Ltd.. (6/29/21). "Press Release: Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim". Hyderabad....
• [9] Libra Therapeutics, Inc.. (9/23/20). "Press Release: Libra Launches with $29M Series A to Develop Novel Therapeutics for Neurodegenerative Diseases". San Diego, CA....
• [10] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.